PHYTONADIONE

Post-LOE

phytonadione

Medica Corp

ANDAINJECTIONINJECTABLE

Approved

Mar 1976

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

PHYTONADIONE (phytonadione) by Medica Corp is 12. Approved for the following coagulation disorders which are due to faulty formation of factors ii, interference with vitamin k activity: • anticoagulant-induced hypoprothrombinemia caused by coumarin, indanedione derivatives and 1 more indications. First approved in 1976.

Drug data last refreshed 19h ago

Mechanism of Action

12.1 Mechanism of Action Phytonadione Injectable Emulsion aqueous colloidal solution of vitamin K 1 for parenteral injection, possesses the same type and degree of activity as does naturally-occurring vitamin K, which is necessary for the production via the liver of active prothrombin (factor II),…

Pharmacologic Class:

Vitamin K

Indications (4)

Worked on PHYTONADIONE at Medica Corp? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.